Probable AD: A plus one or more supportive features B, C, D, or E
Core diagnostic criteria
A. Presence of an early and significant episodic memory impairment that includes the following features:
1. Gradual and progressive change in memory function reported by patients or informants over more than 6 months
E. Proven AD autosomal dominant mutation within the immediate family
Exclusion criteria
History
• Sudden onset
Core diagnostic criteria
A. Presence of an early and significant episodic memory impairment that includes the following features:
1. Gradual and progressive change in memory function reported by patients or informants over more than 6 months
2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall deficit that does not improve significantly or does not normalise with cueing or recognition testing and after effective encoding of information has been previously controlled.
The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances
The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances
Supportive features
B. Presence of medial temporal lobe atrophy
• Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using visual scoring (referenced to well characterised population with age norms) or quantitative volumetry of regions of interest (referenced to well characterised population with age norms)
C. Abnormal cerebrospinal fluid biomarker
• Low amyloid β1–42 concentrations, increased total tau concentrations, or increased phospho-tau concentrations, or combinations of the three
B. Presence of medial temporal lobe atrophy
• Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using visual scoring (referenced to well characterised population with age norms) or quantitative volumetry of regions of interest (referenced to well characterised population with age norms)
C. Abnormal cerebrospinal fluid biomarker
• Low amyloid β1–42 concentrations, increased total tau concentrations, or increased phospho-tau concentrations, or combinations of the three
• Other well validated markers to be discovered in the future
D. Specific pattern on functional neuroimaging with PET
• Reduced glucose metabolism in bilateral temporal parietal regions
D. Specific pattern on functional neuroimaging with PET
• Reduced glucose metabolism in bilateral temporal parietal regions
• Other well validated ligands, including those that foreseeably will emerge such as Pittsburg compound B or FDDNP
E. Proven AD autosomal dominant mutation within the immediate family
Exclusion criteria
History
• Sudden onset
• Early occurrence of the following symptoms: gait disturbances, seizures, behavioural changes
Clinical features
• Focal neurological features including hemiparesis, sensory loss, visual field deficits
Clinical features
• Focal neurological features including hemiparesis, sensory loss, visual field deficits
• Early extrapyramidal signs
Other medical disorders severe enough to account for memory and related symptoms
• Non-AD dementia
Other medical disorders severe enough to account for memory and related symptoms
• Non-AD dementia
• Major depression
• Cerebrovascular disease
• Toxic and metabolic abnormalities, all of which may require specific investigations
• MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are consistent with infectious or vascular insults
Criteria for definite AD
AD is considered definite if the following are present:
• Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of AD; criteria must both be present
Criteria for definite AD
AD is considered definite if the following are present:
• Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of AD; criteria must both be present
• Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; criteria must both be present
No comments:
Post a Comment